Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of nivolumab and/or ipilimumab with or without
azacitidine and to see how well they work in treating patients with myelodysplastic syndrome.
Monoclonal antibodies, such as nivolumab and ipilimumab, may block cancer growth in different
ways by targeting certain cells. Drugs used in chemotherapy, such as azacitidine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving nivolumab and/or ipilimumab
with or without azacitidine may work better in treating myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)